RBC Capital Remains a Buy on Chemours Company (CC)
Jul 3, 2026
RBC Capital reiterated a Buy rating on Chemours with a $26 price target following quarterly earnings reporting $1.38 billion revenue and a $29 million net loss. Analyst consensus remains Moderate Buy with an average target of $25.15.
The Globe and Mail